Sandpoint, ID-based Thorne Research, Inc., has acquired the exclusive global rights to market Q-Cell, an advanced CoQ10 formulation previously marketed under the brand name Q-Best. Q-Cell has a unique, tri-lipid gel-based formulation that has been shown to increase absorption rates by up to 10-fold in comparison to dry powder supplements. The proprietary Q-Cell formulation enables the softgel to prevent crystallization, an after effect of some CoQ10 formulations that can disrupt the absorption process when metabolized in humans.

“Together with our recent alignment with Helsinn Pharmaceuticals, the addition of Q-Cell to our portfolio represents another major milestone in our efforts to develop and market the finest supplements for a range of health needs including supportive care in the oncology market,” said Paul Jacobson, CEO, Thorne Research.